Physician
Neurology
Dr. Eric R. Siemers, MD
Eric Siemers is an expert in the field of Neurology. He attended Indiana University School of Medicine. Indiana University School of Medicine has a rank of 45 in research and a 47 in primary care Eric Siemers is a published doctor as well. He has 88 publications published. The latest was: PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP).
Publications
- Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
- Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
- Anti-Aβ antibody target engagement: commentary regarding Watt et al. Acta Neuropathol 127:803-810 (2014).
- A phase 3 trial of semagacestat for treatment of Alzheimer's disease.
- Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease.
- Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies.
- Enriching Amnestic Mild Cognitive Impairment Populations for Clinical Trials: Optimal Combination of Biomarkers to Predict Conversion to Dementia.
- Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.
- Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid ? Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to...
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup.
- Validation of ELISA Methods for Quantification of Total Tau and Phosporylated-Tau181 in Human Cerebrospinal Fluid with Measurement in Specimens from Two Alzheimer's Di...
- Revision of the criteria for Alzheimer’s disease: A symposium.
- Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.
- A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.
- Ten-year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease.
- Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.
- Commentary on "a roadmap for the prevention of dementia: the inaugural Leon Thal Symposium".
- Partnership between academia and industry for drug discovery in Alzheimer's disease.
- Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase.
- New pathways in drug discovery for Alzheimer's disease.
- Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease".
- Role of biomarkers in studies of presymptomatic Alzheimer's disease.
- Practice effects and the use of alternate forms in serial neuropsychological testing.
- Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: a randomized, controlled study.
- Neuropsychological test performance in healthy volunteers before and after donepezil administration.
- Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease.
- Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia.
- A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's disease.
- Designing clinical trials for early (pre-dementia) Alzheimer''s disease: determining the appropriate population for treatment.
- Report of the task force on designing clinical trials in early (predementia) AD.
- Influence of Competing Distractors on Response Selection in Huntington''s Disease and Parkinson''s Disease.
- Risky decision making in Huntington''s disease.
- A randomized, controlled trial of remacemide for motor fluctuations in Parkinson''s disease.
- Huntington disease.
- Subtle changes among presymptomatic carriers of the Huntington''s disease gene.
- Eye movements in Parkinson's disease: before and after pallidotomy.
- Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene.
- Rate of functional decline in Huntington's disease. Huntington Study Group.
- Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A.
- Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers.
- Multiple system atrophy.
- PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP).
- The treatment of Parkinson's disease: current concepts and rationale.
- Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A.
- Focal dystonia after chemotherapy: a case series.
- Motor changes in presymptomatic Huntington disease gene carriers.
- Anxiety and motor performance in Parkinson's disease.
- Cognitive scores in carriers of Huntington's disease gene compared to noncarriers.
- Quantification of thyrotropin-releasing hormone changes and serotonin content changes following graded spinal cord injury.
- [Chemotherapy of soft tissue sarcomas].
- Early results of combined modality therapy of patients with Ewing''s sarcoma.
- [Results of cytostatic therapy with cyclophosphamide, vincristine, adriamycin and DTIC (CYVADIC) in localized and metastasized osteosarcoma. A retrospective analysis].
- Distribution and uptake of glycine, glutamate and gamma-aminobutyric acid in the vagal nuclei and eight other regions of the rat medulla oblongata.
- Dystonia: therapy with high dosage anticholinergic medication.
- Eaton-Lambert syndrome as a harbinger of recurrent small-cell carcinoma of the cervix with improvement after combination chemotherapy.
- Posttraumatic tic disorder.
- Profile of patients enrolled in a new movement disorder clinic.
- [PASS: a community, system-related program for occupational rehabilitation of chronic psychiatric patients in competitive employment].
- Recent progress in the treatment of Parkinson's disease.
- [Combined chemotherapy and radiotherapy of localized and metastasizing Ewing''s sarcoma (author''s transl)].
- The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma beta-amyloid isoforms using the INNO-BIA plasma Abeta fo...
- How can we recognize "disease modification" effects?
- Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.
- Neuropsychological practice effects and change detection in people with schizophrenia.
- Evaluation of psychological symptoms among presymptomatic HD gene carriers as measured by selected MMPI scales.
- Longitudinal personality changes among presymptomatic Huntington disease gene carriers.
- Biological markers for therapeutic trials in Alzheimer''s disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer''s ...
- The role of biomarkers in clinical trials for Alzheimer disease.
- Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers.
- Cerebrospinal fluid biomarker signature in Alzheimer''s disease neuroimaging initiative subjects.
- Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry.
- Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer''s disease patients by immunoaffinity purification and stable isotope dilution liqui...
- The Alzheimer's disease neuroimaging initiative: perspectives of the Industry Scientific Advisory Board.
- Update on the biomarker core of the Alzheimer''s Disease Neuroimaging Initiative subjects.
- The Alzheimer''s disease neuroimaging initiative: progress report and future plans.
- Modeling screening, prevention, and delaying of Alzheimer''s disease: an early-stage decision analytic model.
- Role of biochemical Alzheimer''s disease biomarkers as end points in clinical trials.
- A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease.
- Developing a national strategy to prevent dementia: Leon Thal Symposium 2009.
- Pharmacological approaches to disease-modifying therapies in Parkinson''s disease.
- Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer''s disease.
- Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic gu...
- Global issues in drug development for Alzheimer's disease.
- AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials.
- Prevention trials in Alzheimer's disease: An EU-US task force report.
- Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.
- Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.
Schools
Indiana University School of Medicine
Ind University Hospital
Doctors Specialties
- Neurology
Accepted Insurances
Education
-
Indiana University School of Medicine
Helpful Reviews
Similar Doctors
|
Dr. Ryan T. Overman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael A. Sermersheim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen D. Rodman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cynthia K. McGarvey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bakul Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen L. Roos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evan J. Templeton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Valerie A. Purvin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Olaniyi O. Osuntokun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alfredo M. Lopez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rohit R. Das, MD |
|
|
Dr. Paul Bustion Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kiran Ivaturi, MD
This Doctor is OpenDoctor Recommended.
|